Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Napazimone

Source date not recordedAnalyse record ↗

Investigational redox-modulating small molecule in a pivotal trial for mtDNA-driven primary mitochondrial disease.

Modality
oral small-molecule NAD+/NADH redox modulator
Availability (US)
Phase 2 FALCON; registry Recruiting in June 2026; company projected enrollment completion during 2026
Biomarkers
NAD+/NADH balance; fatigue; 30-second sit-to-stand; mitochondrial myopathy measures
Hallmark targeted
mitochondrial dysfunction, impaired bioenergetics, redox imbalance
Kind
investigational drug
Clinical trials
NCT05650229 — FALCON randomized placebo-controlled pivotal Phase 2 study in adults with mtDNA-driven primary mitochondrial disease